NO20091553L - Fenylderivater og deres anvendelse som immunmodulatorer - Google Patents

Fenylderivater og deres anvendelse som immunmodulatorer

Info

Publication number: NO20091553L
Authority: NO; Norway
Prior art keywords: immunomodulators; phenyl derivatives; derivatives; formula; preparation
Prior art date: 2006-09-21

Application number

NO20091553A

Other languages

English (en)

Norwegian (no)

Inventor

Martin Bolli

Oliver Nayler

Claus Mueller

Boris Mathys

David Lehmann

Beat Steiner

Jorg Velker

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-21

Filing date

2009-04-20

Publication date

2009-04-20

2009-04-20 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2009-04-20 Publication of NO20091553L publication Critical patent/NO20091553L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

NO20091553A 2006-09-21 2009-04-20 Fenylderivater og deres anvendelse som immunmodulatorer NO20091553L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IB2006053426		2006-09-21
PCT/IB2007/052746 WO2008035239A1 (fr)	2006-09-21	2007-07-10	Dérivés phényliques et utilisation de ceux-ci en tant qu'immunomodulateurs

Publications (1)

Publication Number	Publication Date
NO20091553L true NO20091553L (no)	2009-04-20

Family

ID=38753508

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20091553A NO20091553L (no)	2006-09-21	2009-04-20	Fenylderivater og deres anvendelse som immunmodulatorer

Country Status (15)

Country	Link
US (1)	US8044076B2 (fr)
EP (1)	EP2069318B1 (fr)
JP (1)	JP5250556B2 (fr)
KR (1)	KR20090051774A (fr)
CN (1)	CN101522645B (fr)
AU (1)	AU2007298593A1 (fr)
BR (1)	BRPI0716909A2 (fr)
CA (1)	CA2662673A1 (fr)
ES (1)	ES2393412T3 (fr)
IL (1)	IL197693A0 (fr)
MA (1)	MA30784B1 (fr)
MX (1)	MX2009002915A (fr)
NO (1)	NO20091553L (fr)
RU (1)	RU2442780C2 (fr)
WO (1)	WO2008035239A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY149853A (en)	2006-09-07	2013-10-31	Actelion Pharmaceuticals Ltd	Pyridin-4-yl derivatives as immunomodulating agents
AR062684A1 (es) *	2006-09-08	2008-11-26	Actelion Pharmaceuticals Ltd	Compuestos derivados de piridin-3- ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos
AU2007334436A1 (en)	2006-12-15	2008-06-26	Abbott Laboratories	Novel oxadiazole compounds
DK2125797T3 (da) *	2007-03-16	2014-02-10	Actelion Pharmaceuticals Ltd	Aminopyridinderivater som s1p1/edg1-receptoragonister
HRP20110449T1 (hr) *	2007-08-17	2011-07-31	Actelion Pharmaceuticals Ltd.	Derivati piridina kao modulatori receptora s1p1/edg1
ES2449749T3 (es) *	2007-11-01	2014-03-21	Actelion Pharmaceuticals Ltd.	Nuevos derivados de pirimidina
CA2714665A1 (fr) *	2008-03-06	2009-09-11	Actelion Pharmaceuticals Ltd	Composes de pyridine
US20110046170A1 (en) *	2008-03-06	2011-02-24	Martin Bolli	Novel pyrimidine-pyridine derivatives
KR20100125380A (ko) *	2008-03-07	2010-11-30	액테리온 파마슈티칼 리미티드	신규한 아미노메틸 벤젠 유도체
JP5435745B2 (ja) *	2008-03-07	2014-03-05	アクテリオンファーマシューティカルズリミテッド	免疫調節剤としてのピリジン−２−イル誘導体
BRPI0909625B1 (pt)	2008-03-17	2021-09-08	Actelion Pharmaceuticals Ltd	Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1
US8580841B2 (en)	2008-07-23	2013-11-12	Arena Pharmaceuticals, Inc.	Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
PT2307007E (pt) *	2008-07-23	2014-11-13	Novartis Ag	Moduladores do receptor esfingosina 1 fosfato e sua utilização para tratamento de inflamação muscular
CN105816453B (zh)	2008-08-27	2021-03-05	艾尼纳制药公司	用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物
CN102361869A (zh)	2009-01-23	2012-02-22	百时美施贵宝公司	在治疗自身免疫性疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物
JP2012515789A (ja)	2009-01-23	2012-07-12	ブリストル−マイヤーズスクイブカンパニー	スフィンゴシン−１−リン酸アゴニストとしてのピラゾール−１，２，４−オキサジアゾール誘導体
EP2382212B1 (fr)	2009-01-23	2014-07-16	Bristol-Myers Squibb Company	Dérivés d'oxadiazole substitués comme agonistes de s1p dans le traitement de maladies auto-immunes et inflammatoires
KR101409131B1 (ko)	2009-07-16	2014-06-17	액테리온 파마슈티칼 리미티드	피리딘-4-일 유도체
US8399451B2 (en)	2009-08-07	2013-03-19	Bristol-Myers Squibb Company	Heterocyclic compounds
CA2780772C (fr) *	2009-11-13	2018-01-16	Receptos, Inc.	Modulateurs selectifs du recepteur de sphingosine-1-phosphate et procedes de synthese chirale
SG182610A1 (en)	2010-01-27	2012-08-30	Arena Pharm Inc	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA2789480A1 (fr)	2010-03-03	2011-09-09	Arena Pharmaceuticals, Inc.	Procedes de synthese de modulateurs des recepteurs s1p1 et leurs formes cristallines
WO2011133734A1 (fr)	2010-04-23	2011-10-27	Bristol-Myers Squibb Company	Amides d'acide 4-(5-isoxazolyl ou 5-pyrazolyl-1,2,4-oxadiazol-3-yl)-mandélique comme agonistes du récepteur de la sphingosine-1-phosphate de type 1
CN103124727B (zh)	2010-07-20	2015-03-25	百时美施贵宝公司	取代的3-苯基-1,2,4-噁二唑化合物
CN103237795B (zh)	2010-09-24	2015-10-21	百时美施贵宝公司	经取代的噁二唑化合物及其作为s1p1激动剂的用途
WO2012098505A1 (fr)	2011-01-19	2012-07-26	Actelion Pharmaceuticals Ltd	Dérivés de 2-methoxy-pyridin-4-yl
WO2012118935A1 (fr)	2011-03-03	2012-09-07	Proteotech Inc	Composés pour le traitement de maladies neurodégénératives
EP2753608A1 (fr)	2011-09-08	2014-07-16	Allergan, Inc.	Modulateurs de récepteurs de 3-(4-(5-phényl-1,2,4-oxadiazol-3-yl)phénoxy)propan-2-ol en tant que modulateurs de récepteurs de sphingosine-1-phosphate
HUE050733T2 (hu)	2012-08-17	2021-01-28	Actelion Pharmaceuticals Ltd	Eljárás (2Z,5Z)-5-(3-klór-4-((R)-2,3-dihidroxipropoxi)benzilidén)-2-(pro-pilimino)-3-(O-tolil)tiazolidin-4-on elõállítására és ezen eljárásban alkalmazott köztitermék
EA029309B1 (ru)	2013-03-15	2018-03-30	Идорсиа Фармасьютиклз Лтд	Производные пиридин-4-ила в качестве агонистов s1p/edg1
US11007175B2 (en)	2015-01-06	2021-05-18	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the S1P1 receptor
EP3298008B1 (fr)	2015-05-20	2019-11-20	Idorsia Pharmaceuticals Ltd	Forme cristalline du composé (s)-3-{4-[5-(2-cyclopentyl-6-méthoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-éthyl-6-méthyl-phénoxy}-propane-1,2-diol
US10111841B2 (en)	2015-06-19	2018-10-30	University Of South Florida	Stabilization of alcohol intoxication-induced cardiovascular instability
BR112017027656B1 (pt)	2015-06-22	2023-12-05	Arena Pharmaceuticals, Inc.	Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
JP2020507610A (ja)	2017-02-16	2020-03-12	アリーナファーマシューティカルズ，インコーポレイテッド	腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
CA3053418A1 (fr)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Composes et methodes de traitement de l'angiocholite biliaire primitive
BR112020024762A2 (pt)	2018-06-06	2021-03-23	Arena Pharmaceuticals, Inc.	métodos de tratamento de condições relacionadas ao receptor s1p1
CN119751336A (zh)	2018-09-06	2025-04-04	艾尼纳制药公司	可用于治疗自身免疫性病症和炎性病症的化合物
EP4173485A1 (fr)	2021-10-27	2023-05-03	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Composés inhibant l'agrégation de protéine pour la lutte contre les maladies des plantes

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS51143669A (en) *	1975-06-06	1976-12-10	Takeda Chem Ind Ltd	A process for preparing 1,2,4- oxadiazole derivatives
AU7686891A (en)	1990-04-05	1991-10-30	American National Red Cross, The	A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
JPH1046149A (ja) *	1996-07-31	1998-02-17	Canon Inc	液晶組成物の調製方法
EP1070080A4 (fr)	1998-03-09	2004-12-29	Smithkline Beecham Corp	POLYNUCLEOTIDES ET POLYPEPTIDES D'EDG-1c HUMAIN ET LEURS PROCEDES D'UTILISATION
ATE307129T1 (de)	1999-08-19	2005-11-15	Nps Pharma Inc	Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren
US6579880B2 (en) *	2000-06-06	2003-06-17	Ortho-Mcneil Pharmaceutical, Inc.	Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
PL369598A1 (en)	2001-02-21	2005-05-02	Nps Pharmaceuticals, Inc.	Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
JP4709488B2 (ja)	2002-01-18	2011-06-22	メルク・シャープ・エンド・ドーム・コーポレイション	Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
CA2484233A1 (fr) *	2002-05-13	2003-11-27	Eli Lilly And Company	Composes multicycliques que l'on utilise comme antagonistes de l'hormone de concentration de melanine dans le traitement de l'obesite et du diabete
JP2005533058A (ja) *	2002-06-17	2005-11-04	メルク　エンド　カムパニー　インコーポレーテッド	Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
AU2003279915A1 (en)	2002-10-15	2004-05-04	Merck And Co., Inc.	Process for making azetidine-3-carboxylic acid
WO2004103279A2 (fr)	2003-05-15	2004-12-02	Merck & Co., Inc.	3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles servant d'agonistes du recepteur s1p
WO2005014525A2 (fr)	2003-08-12	2005-02-17	Mitsubishi Pharma Corporation	Compose bi-aryle presentant une activite immunosuppressive
EP1670463A2 (fr)	2003-10-01	2006-06-21	Merck & Co., Inc.	1,2,4-oxadiazoles substitues 3,5-aryle, heteroaryle ou cycloalkyle servant d'agonistes du recepteur s1p
CN1894225A (zh)	2003-12-17	2007-01-10	默克公司	作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯
EP2336113A1 (fr)	2004-05-29	2011-06-22	7TM Pharma A/S	Ligands de récepteur CRTH2 à usage médical
UA76239C2 (en) *	2004-06-03	2006-07-17	Labour Red Banner Order Dnipro	A method for producing 2,5-di(p-aminophenyl)-1,3,4- oxadiazole
EP2371811B1 (fr) *	2004-12-13	2014-10-08	Ono Pharmaceutical Co., Ltd.	Dérivés d'acide azétidinecarboxylique et leur utilisation médicinale
HRP20110613T1 (hr)	2005-03-23	2011-09-30	Actelion Pharmaceuticals Ltd.	Hidrogenizirani derivati benzo[c] tiofena kao imunomodulatori
JP2008539195A (ja)	2005-04-26	2008-11-13	ノイロサーチアクティーゼルスカブ	新規のオキサジアゾール誘導体及びそれらの医学的使用
BRPI0612028A2 (pt)	2005-06-08	2010-10-13	Novartis Ag	oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
WO2006135694A2 (fr)	2005-06-10	2006-12-21	Acadia Pharmaceuticals Inc.	Composes modulateurs d'uii et utilisation
WO2007001973A1 (fr)	2005-06-28	2007-01-04	Astrazeneca Ab	Utilisation
GB0601744D0 (en)	2006-01-27	2006-03-08	Novartis Ag	Organic compounds
EP2258700A1 (fr)	2006-05-09	2010-12-08	Pfizer Products Inc.	Dérivés d'acides aminés cycloalkyles et compositions pharmaceutiques les contenant
MY149853A (en)	2006-09-07	2013-10-31	Actelion Pharmaceuticals Ltd	Pyridin-4-yl derivatives as immunomodulating agents
AR062684A1 (es)	2006-09-08	2008-11-26	Actelion Pharmaceuticals Ltd	Compuestos derivados de piridin-3- ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos
EP2081916A1 (fr)	2006-09-29	2009-07-29	Novartis AG	Dérivés d'oxadiazole ayant des propriétés anti-inflammatoires et immuno-suppressives
AU2007334436A1 (en)	2006-12-15	2008-06-26	Abbott Laboratories	Novel oxadiazole compounds
WO2008091967A1 (fr)	2007-01-26	2008-07-31	Smithkline Beecham Corporation	Composés chimiques
DK2125797T3 (da)	2007-03-16	2014-02-10	Actelion Pharmaceuticals Ltd	Aminopyridinderivater som s1p1/edg1-receptoragonister
ES2449749T3 (es)	2007-11-01	2014-03-21	Actelion Pharmaceuticals Ltd.	Nuevos derivados de pirimidina
CA2714665A1 (fr)	2008-03-06	2009-09-11	Actelion Pharmaceuticals Ltd	Composes de pyridine
US20110046170A1 (en)	2008-03-06	2011-02-24	Martin Bolli	Novel pyrimidine-pyridine derivatives
KR20100125380A (ko)	2008-03-07	2010-11-30	액테리온 파마슈티칼 리미티드	신규한 아미노메틸 벤젠 유도체
JP5435745B2 (ja)	2008-03-07	2014-03-05	アクテリオンファーマシューティカルズリミテッド	免疫調節剤としてのピリジン−２−イル誘導体

2007
- 2007-07-10 JP JP2009528816A patent/JP5250556B2/ja not_active Expired - Fee Related
- 2007-07-10 ES ES07805099T patent/ES2393412T3/es active Active
- 2007-07-10 AU AU2007298593A patent/AU2007298593A1/en not_active Abandoned
- 2007-07-10 MX MX2009002915A patent/MX2009002915A/es not_active Application Discontinuation
- 2007-07-10 WO PCT/IB2007/052746 patent/WO2008035239A1/fr not_active Ceased
- 2007-07-10 US US12/442,203 patent/US8044076B2/en not_active Expired - Fee Related
- 2007-07-10 KR KR1020097006865A patent/KR20090051774A/ko not_active Withdrawn
- 2007-07-10 EP EP07805099A patent/EP2069318B1/fr active Active
- 2007-07-10 RU RU2009114749/04A patent/RU2442780C2/ru not_active IP Right Cessation
- 2007-07-10 CA CA002662673A patent/CA2662673A1/fr not_active Abandoned
- 2007-07-10 CN CN2007800354771A patent/CN101522645B/zh not_active Expired - Fee Related
- 2007-09-10 BR BRPI0716909-4A patent/BRPI0716909A2/pt not_active IP Right Cessation
2009
- 2009-03-19 IL IL197693A patent/IL197693A0/en unknown
- 2009-04-10 MA MA31773A patent/MA30784B1/fr unknown
- 2009-04-20 NO NO20091553A patent/NO20091553L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP2069318A1 (fr)	2009-06-17
BRPI0716909A2 (pt)	2013-11-05
RU2009114749A (ru)	2010-10-27
KR20090051774A (ko)	2009-05-22
JP5250556B2 (ja)	2013-07-31
MX2009002915A (es)	2009-03-31
AU2007298593A1 (en)	2008-03-27
CA2662673A1 (fr)	2008-03-27
WO2008035239A1 (fr)	2008-03-27
JP2010504320A (ja)	2010-02-12
IL197693A0 (en)	2009-12-24
MA30784B1 (fr)	2009-10-01
RU2442780C2 (ru)	2012-02-20
CN101522645B (zh)	2013-01-09
ES2393412T3 (es)	2012-12-21
US20100087495A1 (en)	2010-04-08
EP2069318B1 (fr)	2012-09-12
US8044076B2 (en)	2011-10-25
CN101522645A (zh)	2009-09-02

Publication	Publication Date	Title
NO20091553L (no)	2009-04-20	Fenylderivater og deres anvendelse som immunmodulatorer
NO20076648L (no)	2008-03-17	Novel thiophene derivatives
NO20090628L (no)	2009-04-21	Pyridizinon derivativater
NO20083427L (no)	2008-10-14	Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20091395L (no)	2009-04-06	Nye tiofenderivater
NO20091409L (no)	2009-04-07	Pyridin-3-yl-derivater som immunmodulerende midler
NO20071593L (no)	2007-05-22	Pyrimidinderivater
NO20070224L (no)	2007-04-02	2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20074275L (no)	2007-09-27	2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20072963L (no)	2007-08-03	5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
NO20082090L (no)	2008-05-20	Pyridopyrimidinoninhibitorer av P13K alfa
NO20082793L (no)	2008-06-20	Nye tiofenderivater
NO20073791L (no)	2007-08-30	Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20091889L (no)	2009-06-17	Inhibitorer av spiroketon acetyl-CoA karboksylase
EA201200049A1 (ru)	2012-08-30	1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
EA201100503A1 (ru)	2011-10-31	Глюкозидные производные и их применения
NO20080675L (no)	2008-03-13	P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20075299L (no)	2007-12-27	Hydrogenated benzo (c) thiophene derivatives as immunomodulators
NO20084418L (no)	2008-12-23	Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
NO20071504L (no)	2007-05-25	Pyrimidinderivanter.
NO20066055L (no)	2007-01-24	Pyridinderivater
NO20081942L (no)	2008-04-23	Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
NO20081217L (no)	2008-04-15	Nye benzotiazolonderivater
NO20082496L (no)	2008-07-24	Pyrazinderivater
NO20090994L (no)	2009-05-04	2-aminobenzoxazol karboxamider som 5HT3 modulatorer

Legal Events

Date	Code	Title	Description
2013-03-11	FC2A	Withdrawal, rejection or dismissal of laid open patent application